The polymorphic inheritance of DIO2 rs225014 may predict body weight variation after Graves’ disease treatment
AUTOR(ES)
Comarella, Ana Paula; Vilagellin, Danilo; Bufalo, Natassia Elena; Euflauzino, Jessica Ferreira; Teixeira, Elisangela de Souza; Miklos, Ana Beatriz Pinotti Pedro; Santos, Roberto Bernardo dos; Romaldini, João H.; Ward, Laura S.
FONTE
Arch. Endocrinol. Metab.
DATA DE PUBLICAÇÃO
2020-12
RESUMO
ABSTRACT Objective: We aimed to investigate the role of DIO2 polymorphisms rs225014 and rs12885300 in Graves’ disease patients, mainly for controlling body weight following treatment. Subjects and methods: We genotyped 280 GD patients by the time of diagnosis and 297 healthy control individuals using a TaqMan SNP Genotyping technique. We followed up 141 patients for 18.94 ± 6.59 months after treatment. Results: There was no relationship between the investigated polymorphisms with susceptibility to GD and gain or loss of weight after GD treatment. However, the polymorphic inheritance (CC+CT genotype) of DIO2 rs225014 was associated with a lower body weight variation after GD treatment (4.26 ± 6.25 kg) when compared to wild type TT genotype (6.34 ± 7.26 kg; p = 0.0456 adjusted for the follow-up time). This data was confirmed by a multivariate analysis (p = 0.0138) along with a longer follow-up period (p = 0.0228), older age (p = 0.0306), treatment with radioiodine (p-value = 0.0080) and polymorphic inheritance of DIO2 rs12885300 (p = 0.0306). Conclusion: We suggest that DIO2 rs225014 genotyping may have an auxiliary role in predicting the post-treatment weight behavior of GD patients.
Documentos Relacionados
- TSH-receptor antibodies may prevent bone loss in pre- and postmenopausal women with Graves' disease and Graves' orbitopathy
- Thyroid hormone transport in the serum of patients with thyrotoxic graves' disease before and after treatment
- Neonatal Graves' disease.
- Graves' Disease and Pulmonary Hypertension: Report of 2 Cases
- Graves' disease in children